ReviewCurrent opinion in investigational drugs (London, England : 2000)2010
Development of therapeutic agents for older patients with acute myelogenous leukemia.
Review in Current opinion in investigational drugs (London, England : 2000), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Trial
- Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy.Frontiers in pharmacology · 2024Review
- The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.The Korean journal of internal medicine · 2023Article
- Review
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2020Article
- Immunological effects of hypomethylating agents.Expert review of hematology · 2017Review
- Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.Current drug targets · 2017Review
- Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Journal of clinical medicine · 2015Article
- Adult Acute Myeloid Leukemia Long-term Survivors.Journal of leukemia (Los Angeles, Calif.) · 2014Article
- Materials innovation for co-delivery of diverse therapeutic cargos.RSC advances · 2013Article
- Minimal residual disease in acute myeloid leukaemia.Nature reviews. Clinical oncology · 2013Review
- Treatment of elderly acute myeloid leukemia patients.Current treatment options in oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.
Indexed as
Identifiers
20496262PMC4699173W2473251246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.